purchase customization

1 Study Coverage
1.1 Cancer Drug based on PARP Inhibitor Product Introduction
1.2 Market by Type
1.2.1 Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.3 Market by Application
1.3.1 Global Cancer Drug based on PARP Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Cancer Drug based on PARP Inhibitor Sales Estimates and Forecasts 2017-2028
2.2 Global Cancer Drug based on PARP Inhibitor Revenue Estimates and Forecasts 2017-2028
2.3 Global Cancer Drug based on PARP Inhibitor Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Cancer Drug based on PARP Inhibitor Sales by Region
2.4.1 Global Cancer Drug based on PARP Inhibitor Sales by Region (2017-2022)
2.4.2 Global Sales Cancer Drug based on PARP Inhibitor by Region (2023-2028)
2.5 Global Cancer Drug based on PARP Inhibitor Revenue by Region
2.5.1 Global Cancer Drug based on PARP Inhibitor Revenue by Region (2017-2022)
2.5.2 Global Cancer Drug based on PARP Inhibitor Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Cancer Drug based on PARP Inhibitor Sales by Manufacturers
3.1.1 Global Top Cancer Drug based on PARP Inhibitor Manufacturers by Sales (2017-2022)
3.1.2 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Cancer Drug based on PARP Inhibitor in 2021
3.2 Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers
3.2.1 Global Cancer Drug based on PARP Inhibitor Revenue by Manufacturers (2017-2022)
3.2.2 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Cancer Drug based on PARP Inhibitor Revenue in 2021
3.3 Global Cancer Drug based on PARP Inhibitor Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Cancer Drug based on PARP Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Cancer Drug based on PARP Inhibitor Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Cancer Drug based on PARP Inhibitor Sales by Type
4.1.1 Global Cancer Drug based on PARP Inhibitor Historical Sales by Type (2017-2022)
4.1.2 Global Cancer Drug based on PARP Inhibitor Forecasted Sales by Type (2023-2028)
4.1.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Type (2017-2028)
4.2 Global Cancer Drug based on PARP Inhibitor Revenue by Type
4.2.1 Global Cancer Drug based on PARP Inhibitor Historical Revenue by Type (2017-2022)
4.2.2 Global Cancer Drug based on PARP Inhibitor Forecasted Revenue by Type (2023-2028)
4.2.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Type (2017-2028)
4.3 Global Cancer Drug based on PARP Inhibitor Price by Type
4.3.1 Global Cancer Drug based on PARP Inhibitor Price by Type (2017-2022)
4.3.2 Global Cancer Drug based on PARP Inhibitor Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Cancer Drug based on PARP Inhibitor Sales by Application
5.1.1 Global Cancer Drug based on PARP Inhibitor Historical Sales by Application (2017-2022)
5.1.2 Global Cancer Drug based on PARP Inhibitor Forecasted Sales by Application (2023-2028)
5.1.3 Global Cancer Drug based on PARP Inhibitor Sales Market Share by Application (2017-2028)
5.2 Global Cancer Drug based on PARP Inhibitor Revenue by Application
5.2.1 Global Cancer Drug based on PARP Inhibitor Historical Revenue by Application (2017-2022)
5.2.2 Global Cancer Drug based on PARP Inhibitor Forecasted Revenue by Application (2023-2028)
5.2.3 Global Cancer Drug based on PARP Inhibitor Revenue Market Share by Application (2017-2028)
5.3 Global Cancer Drug based on PARP Inhibitor Price by Application
5.3.1 Global Cancer Drug based on PARP Inhibitor Price by Application (2017-2022)
5.3.2 Global Cancer Drug based on PARP Inhibitor Price Forecast by Application (2023-2028)
6 North America
6.1 North America Cancer Drug based on PARP Inhibitor Market Size by Type
6.1.1 North America Cancer Drug based on PARP Inhibitor Sales by Type (2017-2028)
6.1.2 North America Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2028)
6.2 North America Cancer Drug based on PARP Inhibitor Market Size by Application
6.2.1 North America Cancer Drug based on PARP Inhibitor Sales by Application (2017-2028)
6.2.2 North America Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2028)
6.3 North America Cancer Drug based on PARP Inhibitor Market Size by Country
6.3.1 North America Cancer Drug based on PARP Inhibitor Sales by Country (2017-2028)
6.3.2 North America Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Cancer Drug based on PARP Inhibitor Market Size by Type
7.1.1 Europe Cancer Drug based on PARP Inhibitor Sales by Type (2017-2028)
7.1.2 Europe Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2028)
7.2 Europe Cancer Drug based on PARP Inhibitor Market Size by Application
7.2.1 Europe Cancer Drug based on PARP Inhibitor Sales by Application (2017-2028)
7.2.2 Europe Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2028)
7.3 Europe Cancer Drug based on PARP Inhibitor Market Size by Country
7.3.1 Europe Cancer Drug based on PARP Inhibitor Sales by Country (2017-2028)
7.3.2 Europe Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Cancer Drug based on PARP Inhibitor Market Size by Type
8.1.1 Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Type (2017-2028)
8.1.2 Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2028)
8.2 Asia Pacific Cancer Drug based on PARP Inhibitor Market Size by Application
8.2.1 Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Application (2017-2028)
8.2.2 Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2028)
8.3 Asia Pacific Cancer Drug based on PARP Inhibitor Market Size by Region
8.3.1 Asia Pacific Cancer Drug based on PARP Inhibitor Sales by Region (2017-2028)
8.3.2 Asia Pacific Cancer Drug based on PARP Inhibitor Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Cancer Drug based on PARP Inhibitor Market Size by Type
9.1.1 Latin America Cancer Drug based on PARP Inhibitor Sales by Type (2017-2028)
9.1.2 Latin America Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2028)
9.2 Latin America Cancer Drug based on PARP Inhibitor Market Size by Application
9.2.1 Latin America Cancer Drug based on PARP Inhibitor Sales by Application (2017-2028)
9.2.2 Latin America Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2028)
9.3 Latin America Cancer Drug based on PARP Inhibitor Market Size by Country
9.3.1 Latin America Cancer Drug based on PARP Inhibitor Sales by Country (2017-2028)
9.3.2 Latin America Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Type
10.1.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Type (2017-2028)
10.1.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Type (2017-2028)
10.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Application
10.2.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Application (2017-2028)
10.2.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Application (2017-2028)
10.3 Middle East and Africa Cancer Drug based on PARP Inhibitor Market Size by Country
10.3.1 Middle East and Africa Cancer Drug based on PARP Inhibitor Sales by Country (2017-2028)
10.3.2 Middle East and Africa Cancer Drug based on PARP Inhibitor Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Overview
11.1.3 AstraZeneca Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 AstraZeneca Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AstraZeneca Recent Developments
11.2 Merck & Co
11.2.1 Merck & Co Corporation Information
11.2.2 Merck & Co Overview
11.2.3 Merck & Co Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Merck & Co Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck & Co Recent Developments
11.3 GSK
11.3.1 GSK Corporation Information
11.3.2 GSK Overview
11.3.3 GSK Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 GSK Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GSK Recent Developments
11.4 Clovis Oncology
11.4.1 Clovis Oncology Corporation Information
11.4.2 Clovis Oncology Overview
11.4.3 Clovis Oncology Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Clovis Oncology Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Clovis Oncology Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Overview
11.5.3 Pfizer Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Pfizer Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Pfizer Recent Developments
11.6 Zai Lab
11.6.1 Zai Lab Corporation Information
11.6.2 Zai Lab Overview
11.6.3 Zai Lab Cancer Drug based on PARP Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Zai Lab Cancer Drug based on PARP Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Zai Lab Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Cancer Drug based on PARP Inhibitor Industry Chain Analysis
12.2 Cancer Drug based on PARP Inhibitor Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Cancer Drug based on PARP Inhibitor Production Mode & Process
12.4 Cancer Drug based on PARP Inhibitor Sales and Marketing
12.4.1 Cancer Drug based on PARP Inhibitor Sales Channels
12.4.2 Cancer Drug based on PARP Inhibitor Distributors
12.5 Cancer Drug based on PARP Inhibitor Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Cancer Drug based on PARP Inhibitor Industry Trends
13.2 Cancer Drug based on PARP Inhibitor Market Drivers
13.3 Cancer Drug based on PARP Inhibitor Market Challenges
13.4 Cancer Drug based on PARP Inhibitor Market Restraints
14 Key Findings in The Global Cancer Drug based on PARP Inhibitor Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer